Business context and reporting period
Vera Therapeutics, Inc. filed this Form 10-K for the fiscal year ended December 31, 2022. The clinical-stage biotechnology company had no approved products and generated no product revenue. Its lead candidate, atacicept, is being developed for IgA nephropathy (IgAN) and lupus nephritis (LN); MAU868 is being developed for reactivated BK virus (BKV) infections. The filing was signed March 28, 2023, and includes material subsequent events.
Financial and operating highlights
| Metric | 2022 | 2021 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $69.0 million | $22.5 million |
| General and administrative expense | $21.9 million | $11.9 million |
| Total operating expenses / operating loss | $90.9 million | $34.4 million |
| Net loss | $89.1 million | $32.6 million |
| Net loss per share, basic and diluted | $3.35 | $2.43 |
| Cash used in operating activities | $67.6 million | $23.7 million |
R&D expense increased 207%, principally from clinical development and manufacturing supply for atacicept. G&A expense increased 84%. Operating and net margins are not meaningful because the company had no product revenue. Other income, net, was $1.8 million in 2022; it included interest income and sublease income, partly offset by interest expense and a decline in the value of non-marketable equity securities.
At year-end, cash and cash equivalents were $43.5 million and marketable securities were $71.2 million, for combined cash, cash equivalents and marketable securities of $114.7 million. Current assets were $125.7 million and current liabilities $25.6 million. Debt principal outstanding was $25.0 million, with a net carrying value of $24.8 million. Cash used in investing activities was $70.6 million, largely reflecting purchases of marketable securities less maturities; financing activities provided $101.9 million, mainly from the 2022 follow-on offering and Oxford borrowing.
Material changes versus the prior comparable period
- Net loss rose to $89.1 million from $32.6 million, while operating cash use increased to $67.6 million from $23.7 million.
- R&D costs rose substantially as the ORIGIN IgAN trial advanced, the COMPASS LN trial started, and drug supply was manufactured. The company also recorded $3.7 million of R&D expense related to a 2022 amendment to its Novartis license for MAU868.
- Year-end cash, cash equivalents and marketable securities increased to $114.7 million from $79.7 million. In February 2023, the company raised an additional approximately $107.6 million net from a follow-on offering.
- In January 2023, Vera said it would prioritize atacicept in IgAN, delaying enrollment in the planned LN Phase 3 trial and deferring further resource commitment to MAU868.
Guidance, outlook, risks and unusual items
Management expected year-end 2022 cash, cash equivalents and marketable securities to fund operations for at least 12 months after issuance of the financial statements, while cautioning that estimates depend on assumptions and that substantial additional capital will be needed over the longer term. The company has incurred recurring losses and negative operating cash flows and stated that these conditions raise substantial doubt about its ability to continue as a going concern over the long term.
- Atacicept—IgAN: The Phase 2b ORIGIN trial enrolled 116 patients. January 2023 topline results reported that pooled 75 mg and 150 mg groups met the 24-week primary endpoint versus placebo. In a prespecified per-protocol analysis excluding patients with potentially confounding protocol deviations, the 150 mg dose showed a 41% mean reduction in proteinuria from baseline and a statistically significant 34% placebo-adjusted reduction (p=0.025). The company reported stable eGFR through week 24 and a 60% reduction in Gd-IgA1 at 150 mg. These are topline results; full 36-week results were expected in Q2 2023. Vera planned to start a pivotal Phase 3 trial in Q2 2023, with topline results expected in the first half of 2025 and a potential BLA submission in the second half of 2025 if results are positive.
- Atacicept—LN: A prior Phase 2/3 LN study was terminated after severe hypogammaglobulinemia and pneumonia occurred in patients receiving induction therapy and atacicept. Vera described plans for a Phase 3 study informed by FDA feedback, but then announced it was delaying enrollment while prioritizing IgAN.
- MAU868: Phase 2 results in kidney transplant recipients were described as well tolerated with clinically meaningful antiviral activity through 36 weeks. A Phase 2b or Phase 3 study was contemplated, subject to regulatory alignment; the program was subsequently deprioritized.
- Debt and contingencies: The Oxford facility had $25.0 million drawn at year-end, with up to $25.0 million of additional borrowing capacity then available. It bears a floating rate subject to an 8.25% floor and is secured by company assets, excluding intellectual property, which is subject to a negative pledge. In March 2023, Vera extended the facility maturity to December 2027 and the interest-only period to December 2026, increasing the final payment from 5% to 7% of principal. License agreements also include substantial potential milestones and royalties, including up to $176.5 million in regulatory milestones and $515.0 million in commercial milestones to Ares for atacicept.
- Other events: Following the March 2023 Silicon Valley Bank closure, Vera said it did not expect a material financial-statement impact after federal actions protected depositors. The filing reports no material legal proceedings. Management assessed disclosure controls and internal control over financial reporting as effective at year-end; the auditor did not provide an internal-control attestation.
Key risks include clinical-trial failure or delay, uncertainty around preliminary data and regulatory approval, dependence on third-party manufacturers and CROs, the need for additional financing, competition, and reliance on licensed intellectual property. The company also cited macroeconomic and geopolitical uncertainty and potential effects on capital access, costs, and clinical operations.
Important facts investors should verify
- Review final ORIGIN 36-week data and subsequent Phase 3 design, enrollment, and regulatory milestones; distinguish topline and per-protocol findings from final results.
- Confirm the company’s updated cash runway after the February 2023 offering against expected Phase 3 costs and the pace of operating cash use.
- Track Oxford facility draw availability, interest expense, covenants, maturity extension, and the final-payment obligation.
- Assess the safety-monitoring plan for atacicept in LN in light of the prior hypogammaglobulinemia and pneumonia events.
- Monitor the timing and funding implications of Vera’s deferred LN and MAU868 programs, as well as potential license milestones and royalties.